Dulaglutide, a glucagon-like peptide-1 (GLP-1) agonist, is utilized for the management of type 2 diabetes and obesity, typically administered subcutaneously at a dosage of 0.75 mg/0.5 mL once weekly, with adjustments made as needed. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.